Calando inks licensing deal with Cerulean

Calando Pharmaceuticals, a subsidiary of Arrowhead Research, has struck a licensing deal with Cerulean Pharma for Calando's drug delivery platform, Cyclosert, and the associated clinical stage anti-cancer drug, IT-101. Calando, which has been focused on reducing its burn rate, gets $2.4 million upfront and up to $2.75 million in milestones up to an approval. "Calando's cyclodextrin co-polymer based technology is founded on elegant chemistry, and the integration of this platform into our program fully leverages the expertise and capabilities that we have built," said Cerulean CEO Dr. Oliver Fetzer. Release

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.